Numinus Wellness Inc. (T:NUMI)
Business Focus: Biotechnology & Medical Research (NEC)
Nov 29, 2023 04:00 pm ET
Numinus Wellness Inc. Announces Fourth Quarter and Full Year Fiscal 2023 Results
Q4 Fiscal 2023 Highlights
Nov 29, 2023 04:00 pm ET
Numinus Wellness Inc. Announces Fourth Quarter and Full Year Fiscal 2023 Results
Q4 Fiscal 2023 Highlights
Nov 21, 2023 07:00 am ET
Numinus to Host Q4 2023 and Annual Results Conference Call on November 29, 2023
VANCOUVER, BC, Nov. 21, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter and year ended August 31, 2023, after market close on Wednesday, November 29, 2023.
Nov 21, 2023 07:00 am ET
Numinus to Host Q4 2023 and Annual Results Conference Call on November 29, 2023
VANCOUVER, BC, Nov. 21, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter and year ended August 31, 2023, after market close on Wednesday, November 29, 2023.
Oct 03, 2023 07:00 am ET
Numinus Announces Psychedelic Program for Mental Distress Associated with Chronic and Serious Illness through Cedar Clinical Research
VANCOUVER, BC, Oct. 3, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF) – a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is proud to introduce its innovative and comprehensive psychedelic program for individuals suffering from mental distress associated with serious and chronic illness. Operating out of the Numinus Wellness UT and Cedar Clinical Research facilities, the program encompasses four key initiatives that showcase Numinus' commitment to advancing psychedelic research and
Oct 03, 2023 07:00 am ET
Numinus Announces Psychedelic Program for Mental Distress Associated with Chronic and Serious Illness through Cedar Clinical Research
VANCOUVER, BC, Oct. 3, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF) – a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is proud to introduce its innovative and comprehensive psychedelic program for individuals suffering from mental distress associated with serious and chronic illness. Operating out of the Numinus Wellness UT and Cedar Clinical Research facilities, the program encompasses four key initiatives that showcase Numinus' commitment to advancing psychedelic resea
Sep 25, 2023 07:16 pm ET
Numinus Wellness Inc. Announces At-The-Market Offering Equity Program
VANCOUVER, BC, Sept. 25, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), is pleased to announce that it has established an at-the-market equity offering program (the "ATM Program") that allows the Company to issue and sell up to C$10,000,000 of common shares in the capital of the Company (the "Common Shares") from time to time, at the Company's discretion and subject to regulatory requirements. All Common Shares issued under the ATM Program will be sold in transactions that are deemed to be "at-the-market" distributions as defined in National Instr
Sep 25, 2023 07:16 pm ET
Numinus Wellness Inc. Announces At-The-Market Offering Equity Program
VANCOUVER, BC, Sept. 25, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), is pleased to announce that it has established an at-the-market equity offering program (the "ATM Program") that allows the Company to issue and sell up to C$10,000,000 of common shares in the capital of the Company (the "Common Shares") from time to time, at the Company's discretion and subject to regulatory requirements. All Common Shares issued under the ATM Program will be sold in transactions that are deemed to be "at-the-market" distributions as defined in Nationa
Sep 19, 2023 07:00 am ET
Numinus Congratulates MAPS on its Phase 3 Study Results Published in Nature Medicine
Study Results are widely regarded as the final step before MDMA-assisted therapy is reviewed by the FDA for wider patient access.Numinus continues to support greater access to these important therapies, through its growing psychedelic-assisted therapy practitioner training programsVANCOUVER, BC, Sept. 19, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies congratulates the Multidisciplinary Association of Psychedelics Studies ("MAPS") o
Sep 19, 2023 07:00 am ET
Numinus Congratulates MAPS on its Phase 3 Study Results Published in Nature Medicine
Study Results are widely regarded as the final step before MDMA-assisted therapy is reviewed by the FDA for wider patient access.Numinus continues to support greater access to these important therapies, through its growing psychedelic-assisted therapy practitioner training programsVANCOUVER, BC, Sept. 19, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies congratulates the Multidisciplinary Association of Psychedelics Studies ("M
Sep 18, 2023 06:45 pm ET
Numinus Takes Actions to Accelerate its Path to Profitability by Focusing on Positive Cash Flow Generating Operations
The Company is ceasing operating activities at Numinus Bioscience – its non-revenue producing research lab, and is consolidating clinic operations in certain regions to enhance company performance and improve the overall client experience.Collectively, these activities are expected to save nearly C$1 million of annualized cash expenses, which will improve company margins and support its path to profitability.VANCOUVER, BC, Sept. 18, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe
Sep 18, 2023 06:45 pm ET
Numinus Takes Actions to Accelerate its Path to Profitability by Focusing on Positive Cash Flow Generating Operations
The Company is ceasing operating activities at Numinus Bioscience – its non-revenue producing research lab, and is consolidating clinic operations in certain regions to enhance company performance and improve the overall client experience.Collectively, these activities are expected to save nearly C$1 million of annualized cash expenses, which will improve company margins and support its path to profitability.VANCOUVER, BC, Sept. 18, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments a
Aug 09, 2023 07:00 am ET
Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, August 17, 2023
VANCOUVER, BC, Aug. 9, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF) – a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Nikhil Handa, CFO, will participate in a Water Tower Research Fireside Chat on Thursday, August 17, 2023, at 11:00 a.m. ET / 8:00 a.m. PT.
Jul 17, 2023 04:01 pm ET
Numinus Wellness Inc. Reports Q3 2023 Results
Q3 2023 revenues grew 713.3% year-over-year to $6.0 millionQ3 2023 revenues grew 12.6% from previous quarterGross profit of $2.1 million, increased 1051.6% year-over-yearStaff reductions and operational realignment resulted in $0.6 million of one-time expenses during the quarterCash position of $13.0 million as at May 31, 2023Activities taken during Q3 2023 position the company well for the expected future approval of MDMA-assisted therapyAll financial results are reported in Canadian dollars unless otherwise stated.
Jul 17, 2023 04:01 pm ET
Numinus Wellness Inc. Reports Q3 2023 Results
Q3 2023 revenues grew 713.3% year-over-year to $6.0 millionQ3 2023 revenues grew 12.6% from previous quarterGross profit of $2.1 million, increased 1051.6% year-over-yearStaff reductions and operational realignment resulted in $0.6 million of one-time expenses during the quarterCash position of $13.0 million as at May 31, 2023Activities taken during Q3 2023 position the company well for the expected future approval of MDMA-assisted therapyAll financial results are reported in Canadian dollars unless otherwise stated.
Jul 14, 2023 08:35 am ET
Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from Small Cap Growth Virtual Investor Conference, held on July 13th are now available for online viewing. REGISTER NOW AT:...
Jul 10, 2023 06:29 pm ET
Numinus to Present at the Small Cap Growth Virtual Investor Conference on July 13, 2023
VANCOUVER, BC, July 10, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF) – a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will present live at the Small Cap Growth 50 Virtual Investor Conference, hosted by VirtualInvestorConferences.com, on July 13, 2023.
Jul 10, 2023 06:29 pm ET
Numinus to Present at the Small Cap Growth Virtual Investor Conference on July 13, 2023
VANCOUVER, BC, July 10, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF) – a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will present live at the Small Cap Growth 50 Virtual Investor Conference, hosted by VirtualInvestorConferences.com, on July 13, 2023.
Jul 10, 2023 03:46 pm ET
Small Cap Growth Virtual Investor Conference Agenda Announced for July 13th
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Small Cap Growth Virtual Investor Conference. Individual investors, institutional investors, advisors, and analysts are invited to...
Jun 29, 2023 07:00 am ET
Numinus to Host Q3 2023 Results Conference Call on July 17, 2023
VANCOUVER, BC, June 29, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended May 31, 2023, after market close on Monday, July 17, 2023.
Jun 29, 2023 07:00 am ET
Numinus to Host Q3 2023 Results Conference Call on July 17, 2023
VANCOUVER, BC, June 29, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended May 31, 2023, after market close on Monday, July 17, 2023.
Jun 22, 2023 07:00 am ET
Numinus Announces Agreement with HealingMaps to Drive Strategic Clinic Growth
VANCOUVER, BC, June 22, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF) – a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it has signed an agreement (the "Agreement") with HealingMaps – a source for individuals looking for accurate and honest information about psychedelic-assisted therapy ("PAT"), to increase awareness of Numinus' wellness clinics and the Numinus Network licensing model, and to offer practitioner training information and referrals – exc
Jun 22, 2023 07:00 am ET
Numinus Announces Agreement with HealingMaps to Drive Strategic Clinic Growth
VANCOUVER, BC, June 22, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF) – a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it has signed an agreement (the "Agreement") with HealingMaps – a source for individuals looking for accurate and honest information about psychedelic-assisted therapy ("PAT"), to increase awareness of Numinus' wellness clinics and the Numinus Network licensing model, and to offer practitioner training information and referral
Jun 15, 2023 07:00 am ET
Numinus Announces Partnership with MAPS to Support Therapist Psychedelic Experiential Training
Numinus has submitted a Clinical Trial Application (CTA) to Health Canada to enable MDMA-assisted therapy Experiential Opportunities for practitioners as part of an investigational Phase 1 clinical trial.If approved, Numinus intends to make the Experiential Opportunity available to practitioners as part of its psychedelic-assisted therapy education and training program. If the CTA is approved, MAPS will provide Numinus with permission to use its protocol as part of this Experiential Opportunity, the first such permission granted by MAPS.VANCOUVER, BC, June 15, 2023 /CNW/ - Numinus Wellness
Jun 15, 2023 07:00 am ET
Numinus Announces Partnership with MAPS to Support Therapist Psychedelic Experiential Training
Numinus has submitted a Clinical Trial Application (CTA) to Health Canada to enable MDMA-assisted therapy Experiential Opportunities for practitioners as part of an investigational Phase 1 clinical trial.If approved, Numinus intends to make the Experiential Opportunity available to practitioners as part of its psychedelic-assisted therapy education and training program. If the CTA is approved, MAPS will provide Numinus with permission to use its protocol as part of this Experiential Opportunity, the first such permission granted by MAPS.VANCOUVER, BC, June 15, 2023 /PRNewswire/ - Numinus We
Jun 14, 2023 07:00 am ET
Numinus Appoints New Chief Financial Officer
VANCOUVER, BC, June 14, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced the appointment of Nikhil Handa as Chief Financial Officer, effective June 15, 2023, following a thorough executive search. Current Chief Financial Officer, John Fong, will be stepping down effective end of day today to focus on family health matters. Mr. Fong will remain involved with the Company during the incoming CFO transition period to ensu
Jun 08, 2023 02:15 pm ET
The Power Play by The Market Herald Releases New Interviews with Justera Health, Nextech3D.ai, Numinus Wellness, Sona Nanotech and Fineqia International Discussing Their Latest News
VANCOUVER, BC / ACCESSWIRE / June 8, 2023 / The Power Play by The Market Herald has announced the release of new interviews with Justera Health, Nextech3D.ai, Numinus Wellness, Sona Nanotech and Fineqia International discussing their latest news.
Jun 08, 2023 07:00 am ET
Numinus to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023
VANCOUVER, BC, June 8, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will present at the Healthcare Virtual Conference presented by Maxim Group LLC and hosted by M-Vest, on June 20-22, 2023.
Jun 08, 2023 07:00 am ET
Numinus to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on June 20-22, 2023
VANCOUVER, BC, June 8, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will present at the Healthcare Virtual Conference presented by Maxim Group LLC and hosted by M-Vest, on June 20-22, 2023.
Jun 05, 2023 07:00 am ET
Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed's Phase 2B study evaluating MM-120
VANCOUVER, BC, June 5, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce Cedar Clinical Research (CCR) is a top research site for MindMed's Phase 2b study evaluating MM-120 (lysergide D-tartrate) for General Anxiety Disorder.
Jun 05, 2023 07:00 am ET
Cedar Clinical Research, by Numinus, the top enrolling clinical research site for MindMed's Phase 2B study evaluating MM-120
VANCOUVER, BC, June 5, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce Cedar Clinical Research (CCR) is a top research site for MindMed's Phase 2b study evaluating MM-120 (lysergide D-tartrate) for General Anxiety Disorder.
Jun 02, 2023 07:00 am ET
Numinus to Participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023
VANCOUVER, BC, June 2, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023, at 1:00 p.m. ET / 10:00 a.m. PT.
Jun 02, 2023 07:00 am ET
Numinus to Participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023
VANCOUVER, BC, June 2, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will participate in a Water Tower Research Fireside Chat on Wednesday, June 7, 2023, at 1:00 p.m. ET / 10:00 a.m. PT.
May 30, 2023 07:00 am ET
Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part of large phase 3 study
The research conducted at Cedar Clinical Research in Draper is part of the first ever phase 3 program of psilocybin therapy, and the largest of its kind
May 30, 2023 07:00 am ET
Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part of large phase 3 study
The research conducted at Cedar Clinical Research in Draper is part of the first ever phase 3 program of psilocybin therapy, and the largest of its kind
May 25, 2023 07:00 am ET
Numinus Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy
First Numinus Network™ partner enters into agreementRecent cost containment initiatives have resulted in approximately $4.2 million of annualized savings, extending cash runway Well positioned to provide psychedelic-assisted therapy insurance reimbursement, as a result of recent US insurance payor code approval MDMA-assisted therapy expected to be approved for treatment in US in 2024 – Numinus well positioned to be a key provider of this therapyVANCOUVER, BC, May 25, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advan
May 25, 2023 07:00 am ET
Numinus Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy
First Numinus Network™ partner enters into agreementRecent cost containment initiatives have resulted in approximately $4.2 million of annualized savings, extending cash runway Well positioned to provide psychedelic-assisted therapy insurance reimbursement, as a result of recent US insurance payor code approval MDMA-assisted therapy expected to be approved for treatment in US in 2024 – Numinus well positioned to be a key provider of this therapyVANCOUVER, BC, May 25, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care compan
Apr 18, 2023 03:00 pm ET
The Power Play by The Market Herald Releases New Interviews with Reunion Gold Corp, Numinus Wellness, Core Assets, Blockmate Ventures, BioVaxys Tech, Carlyle Commodities and Belmont Resources Discussi
VANCOUVER, BC / ACCESSWIRE / April 18, 2023 / The Power Play by The Market Herald has announced the release of new interviews with Reunion Gold Corp, Numinus Wellness, Core Assets, Blockmate Ventures, BioVaxys Tech, Carlyle Commodities and Belmont Resources discussing their latest news.
Apr 17, 2023 07:00 am ET
Numinus to Participate in a Water Tower Research Fireside Chat on Wednesday, April 19, 2023
VANCOUVER, BC, April 17, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will participate in a Water Tower Research Fireside Chat on Wednesday, April 19, 2023, at 11:30 a.m. ET / 8:30 a.m. PT.
Apr 17, 2023 07:00 am ET
Numinus to Participate in a Water Tower Research Fireside Chat on Wednesday, April 19, 2023
VANCOUVER, BC, April 17, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will participate in a Water Tower Research Fireside Chat on Wednesday, April 19, 2023, at 11:30 a.m. ET / 8:30 a.m. PT.
Apr 14, 2023 07:00 am ET
Numinus Launches New Website to Enhance its Client Experience
VANCOUVER, BC, April 14, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has launched a new client website at www.numinus.com as part of its branding strategy to align all wellness clinics under the Numinus brand.
Apr 14, 2023 07:00 am ET
Numinus Launches New Website to Enhance its Client Experience
VANCOUVER, BC, April 14, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has launched a new client website at www.numinus.com as part of its branding strategy to align all wellness clinics under the Numinus brand.
Apr 13, 2023 04:01 pm ET
Numinus Wellness Inc. Reports Q2 2023 Results
Q2 2023 revenues grew 581.1% year-over-year to $5.4 millionQ2 2023 gross margin increased to 39.3% from 29.1% in Q2 2022Gross profit of $2.1 million, increased 820.9% year-over-yearStrong cash position of $19.7 millionNew licensing model designed to drive accelerated clinic growth with lower capital expendituresAll financial results are reported in Canadian dollars unless otherwise stated.
Apr 13, 2023 04:01 pm ET
Numinus Wellness Inc. Reports Q2 2023 Results
Q2 2023 revenues grew 581.1% year-over-year to $5.4 millionQ2 2023 gross margin increased to 39.3% from 29.1% in Q2 2022Gross profit of $2.1 million, increased 820.9% year-over-yearStrong cash position of $19.7 millionNew licensing model designed to drive accelerated clinic growth with lower capital expendituresAll financial results are reported in Canadian dollars unless otherwise stated.
Apr 11, 2023 02:49 pm ET
Healing CREI Announces a Partnership with Numinus Wellness Inc.
Lake Worth, Florida--(Newsfile Corp. - April 11, 2023) - Healing Commercial Real Estate Inc. ("Healing CREI" or the "Company"), a data-driven self-managed real estate investment company, today announced that the Company has entered into a partnership with Numinus Wellness Inc. (TSX: NUMI) ("Numinus"), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies to support their newly launched clinic licensing model, named the Numinus Network.
Apr 11, 2023 07:00 am ET
Numinus Launches new Clinic Licensing Platform, the Numinus Network, to Accelerate Expansion
Licensing model enables Numinus to scale with limited capital investment and overheadProvides practitioners with an alternate model, allowing them to retain ownership of their practice and performance while leveraging Numinus patient protocolsNew partnership with Healing Commercial Real Estate Inc. provides Numinus Network licensees with turn-key locations VANCOUVER, BC, April 11, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therap
Apr 11, 2023 07:00 am ET
Numinus Launches new Clinic Licensing Platform, the Numinus Network, to Accelerate Expansion
Licensing model enables Numinus to scale with limited capital investment and overheadProvides practitioners with an alternate model, allowing them to retain ownership of their practice and performance while leveraging Numinus patient protocolsNew partnership with Healing Commercial Real Estate Inc. provides Numinus Network licensees with turn-key locations VANCOUVER, BC, April 11, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted
Mar 30, 2023 07:00 am ET
Numinus to Host Q2 2023 Results Conference Call on April 13, 2023
VANCOUVER, BC, March 30, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended February 28, 2023, after market close on Thursday, April 13, 2023.
Mar 30, 2023 07:00 am ET
Numinus to Host Q2 2023 Results Conference Call on April 13, 2023
VANCOUVER, BC, March 30, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended February 28, 2023, after market close on Thursday, April 13, 2023.
Mar 27, 2023 07:00 am ET
Numinus Launches the Practitioner Certification Pathway - a Complete Psychedelic-Assisted Therapy Training Program
VANCOUVER, BC, March 27, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has launched the Numinus Certification Pathway – a collection of psychedelic-assisted therapy ("PAT") training courses uniquely selected to provide practitioners with complete PAT training, including an experiential component and practicum.
Mar 27, 2023 07:00 am ET
Numinus Launches the Practitioner Certification Pathway - a Complete Psychedelic-Assisted Therapy Training Program
VANCOUVER, BC, March 27, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it has launched the Numinus Certification Pathway – a collection of psychedelic-assisted therapy ("PAT") training courses uniquely selected to provide practitioners with complete PAT training, including an experiential component and practicum.
Mar 22, 2023 07:00 am ET
Numinus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023
VANCOUVER, BC, March 22, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the Sequire Cannabis & Psychedelics Conference to be held virtually on Wednesday, April 5, 2023.
Mar 22, 2023 07:00 am ET
Numinus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023
VANCOUVER, BC, March 22, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the Sequire Cannabis & Psychedelics Conference to be held virtually on Wednesday, April 5, 2023.
Mar 21, 2023 07:00 am ET
Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023
VANCOUVER, BC, March 21, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Reid Robison, Chief Clinical Officer of Numinus, has contributed to studies published in four peer-reviewed papers thus far in 2023 for his work in the treatment of mental health disorders including Post-Traumatic Stress Disorder (PTSD), depression, and anxiety.
Mar 21, 2023 07:00 am ET
Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023
VANCOUVER, BC, March 21, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Reid Robison, Chief Clinical Officer of Numinus, has contributed to studies published in four peer-reviewed papers thus far in 2023 for his work in the treatment of mental health disorders including Post-Traumatic Stress Disorder (PTSD), depression, and anxiety.
Mar 20, 2023 12:05 pm ET
IIROC Trading Halt - NUMI.WT.C
TORONTO, March 20, 2023 /CNW/ - The following issues have been halted by IIROC:
Mar 07, 2023 06:00 am ET
Numinus Wellness Inc. Executives to Present on Panel at Upcoming South by Southwest Conference
CEO and founder, Payton Nyquvest, to be featured on panel titled "Music as Medicine: Music as a Tool For Healing" alongside Dr. Reid Robison, Charlotte James and East Forest
Feb 24, 2023 06:00 am ET
Numinus to Participate in a Water Tower Research Fireside Chat on Tuesday, February 28, 2023
VANCOUVER, BC, Feb. 24, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Dr. Paul Thielking, Chief Science Officer of Numinus, will participate in a Water Tower Research Fireside Chat on Tuesday, February 28, 2023, at 3:00 p.m. ET / 12:00 p.m. PT.
Feb 24, 2023 06:00 am ET
Numinus to Participate in a Water Tower Research Fireside Chat on Tuesday, February 28, 2023
VANCOUVER, BC, Feb. 24, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Dr. Paul Thielking, Chief Science Officer of Numinus, will participate in a Water Tower Research Fireside Chat on Tuesday, February 28, 2023, at 3:00 p.m. ET / 12:00 p.m. PT.
Feb 17, 2023 06:00 am ET
Numinus Expands Research Capabilities with new Phoenix Clinical Research Site
The Phoenix Site is Numinus' Third Research Facility in the US
Feb 17, 2023 06:00 am ET
Numinus Expands Research Capabilities with new Phoenix Clinical Research Site
The Phoenix Site is Numinus' Third Research Facility in the US
Feb 15, 2023 04:00 pm ET
Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders
VANCOUVER, BC, Feb. 15, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting"), held earlier today. A total of 43,610,863 common shares representing 16.6% of the 262,749,836 issued and outstanding common shares of the Company as at the record date of January 16, 2023, were represented either in person or by proxy at the Me
Feb 01, 2023 06:00 am ET
Numinus Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training using Psilocybe Cubensis Tea
Clinical trial will be the first to test whole Psilocybe mushrooms for safety and efficacy in a clinical setting; study is expected to provide important data to support increased access to psilocybin-assisted therapy.Clinical trial will provide experiential training to therapists learning to conduct psilocybin-assisted therapy and will use Numinus Bioscience's Psilocybin Tea, EnfiniTea, for dosing.VANCOUVER, BC, Feb. 1, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-ba
Feb 01, 2023 06:00 am ET
Numinus Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training using Psilocybe Cubensis Tea
Clinical trial will be the first to test whole Psilocybe mushrooms for safety and efficacy in a clinical setting; study is expected to provide important data to support increased access to psilocybin-assisted therapy.Clinical trial will provide experiential training to therapists learning to conduct psilocybin-assisted therapy and will use Numinus Bioscience's Psilocybin Tea, EnfiniTea, for dosing.VANCOUVER, BC, Feb. 1, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evid
Jan 16, 2023 03:01 pm ET
Numinus Wellness Inc. Reports Q1 2023 Results
Q1 2023 revenues grew 618% year-over-year to $5.7 millionQ1 2023 gross margin grew to 41.9% from 31.5% in prior quarterGross profit of $2.4 million, an increase of $1.1 million from prior quarterEnded quarter with cash position of $26.4 millionAll financial results are reported in Canadian dollars unless otherwise stated.
Jan 16, 2023 03:01 pm ET
Numinus Wellness Inc. Reports Q1 2023 Results
Q1 2023 revenues grew 618% year-over-year to $5.7 millionQ1 2023 gross margin grew to 41.9% from 31.5% in prior quarterGross profit of $2.4 million, an increase of $1.1 million from prior quarterEnded quarter with cash position of $26.4 millionAll financial results are reported in Canadian dollars unless otherwise stated.
Jan 04, 2023 06:00 am ET
Numinus to Host Q1 2023 Results Conference Call on January 16, 2023
VANCOUVER, BC, Jan. 4, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended November 30, 2022, after market close on Monday, January 16, 2023.
Jan 04, 2023 06:00 am ET
Numinus to Host Q1 2023 Results Conference Call on January 16, 2023
VANCOUVER, BC, Jan. 4, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended November 30, 2022, after market close on Monday, January 16, 2023.
Dec 29, 2022 11:10 am ET
IIROC Trading Halt - NUMI.WT.B
TORONTO, Dec. 29, 2022 /CNW/ - The following issues have been halted by IIROC:
Dec 19, 2022 06:02 am ET
Dec 16, 2022 08:35 am ET
KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the presentations from its KCSA Mental Health Virtual Investor Conference held on December...
Dec 13, 2022 08:35 am ET
KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th
Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the agenda for the upcoming KCSA Mental Health Virtual Investor Conference to be held on...
Dec 12, 2022 03:10 pm ET
Numinus to Participate in the KCSA Mental Health Virtual Investor Conference on December 15, 2022
VANCOUVER, BC, Dec. 12, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will present at the KCSA Mental Health Investor Conference to be held at VirtualInvestorConferences.com on Thursday, December 15, 2022 at 12:30 p.m. ET / 9:30 a.m. PT.
Dec 12, 2022 03:10 pm ET
Numinus to Participate in the KCSA Mental Health Virtual Investor Conference on December 15, 2022
VANCOUVER, BC, Dec. 12, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will present at the KCSA Mental Health Investor Conference to be held at VirtualInvestorConferences.com on Thursday, December 15, 2022 at 12:30 p.m. ET / 9:30 a.m. PT.
Dec 08, 2022 06:00 am ET
Numinus Submits Clinical Trial Application to Health Canada for Experiential Psilocybin-Assisted Therapy Training Research
New clinical trial will provide experiential training to therapists learning to conduct psilocybin-assisted therapy.Clinical trial dosing will use Numinus Bioscience's Psilocybin Tea, EnfiniTea – one of the first Phase 1 clinical trials that will report on whole Psilocybe mushroom safety.VANCOUVER, BC, Dec. 8, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its research division has submitted a clinical trial ap
Dec 08, 2022 06:00 am ET
Numinus Submits Clinical Trial Application to Health Canada for Experiential Psilocybin-Assisted Therapy Training Research
New clinical trial will provide experiential training to therapists learning to conduct psilocybin-assisted therapy.Clinical trial dosing will use Numinus Bioscience's Psilocybin Tea, EnfiniTea – one of the first Phase 1 clinical trials that will report on whole Psilocybe mushroom safety.VANCOUVER, BC, Dec. 8, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its research division has submitted a clinical t
Nov 30, 2022 07:06 am ET
IIROC Trade Resumption - NUMI
TORONTO, Nov. 30, 2022 /CNW/ - Trading resumes in:
Nov 29, 2022 03:20 pm ET
IIROC Trading Halt - NUMI
TORONTO, Nov. 29, 2022 /CNW/ - The following issues have been halted by IIROC:
Nov 29, 2022 03:15 pm ET
Numinus Wellness Inc. Reports Q4 2022 and Annual Results
Q4 2022 revenues grew 643% year-over-year to $4.2 million Q4 2022 gross margin grew to 31.5%, generated $1.3 million of gross profitCompleted acquisition of Novamind, positioning Numinus as a leading, integrated mental healthcare company providing psychedelic-assisted therapiesEnded quarter with cash position of $33.0 millionAll financial results are reported in Canadian dollars unless otherwise stated.
Nov 29, 2022 03:15 pm ET
Numinus Wellness Inc. Reports Q4 2022 and Annual Results
Q4 2022 revenues grew 643% year-over-year to $4.2 million Q4 2022 gross margin grew to 31.5%, generated $1.3 million of gross profitCompleted acquisition of Novamind, positioning Numinus as a leading, integrated mental healthcare company providing psychedelic-assisted therapiesEnded quarter with cash position of $33.0 millionAll financial results are reported in Canadian dollars unless otherwise stated.
Nov 22, 2022 06:00 am ET
Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022
VANCOUVER, BC, Nov. 22, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022, at 11:00 a.m. ET / 8:00 a.m. PT.
Nov 22, 2022 06:00 am ET
Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022
VANCOUVER, BC, Nov. 22, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO, will participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022, at 11:00 a.m. ET / 8:00 a.m. PT.
Nov 15, 2022 06:00 am ET
Numinus to Host Q4 and Year End 2022 Results Conference Call on November 29, 2022
VANCOUVER, BC, Nov. 15, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter and year ended August 31, 2022, after market close on Tuesday, November 29, 2022.
Nov 15, 2022 06:00 am ET
Numinus to Host Q4 and Year End 2022 Results Conference Call on November 29, 2022
VANCOUVER, BC, Nov. 15, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter and year ended August 31, 2022, after market close on Tuesday, November 29, 2022.
Nov 01, 2022 07:00 am ET
Numinus Re-Launches "Psychedelic Therapy Frontiers" Podcast with additional hosts and topics
Series is Devoted to Exploring The Psychedelic Renaissance and Cultivating a Healthy Mind, Body and Spirit
Nov 01, 2022 07:00 am ET
Numinus Re-Launches "Psychedelic Therapy Frontiers" Podcast with additional hosts and topics
Series is Devoted to Exploring The Psychedelic Renaissance and Cultivating a Healthy Mind, Body and Spirit
Oct 31, 2022 07:00 am ET
Numinus to Participate in Wonderland: Miami on November 3-5, 2022
VANCOUVER, BC, Oct. 31, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in Wonderland: Miami hosted by Microdose to be held at the Mana Wynwood Convention Center in Miami, FL on November 3-5, 2022.
Oct 31, 2022 07:00 am ET
Numinus to Participate in Wonderland: Miami on November 3-5, 2022
VANCOUVER, BC, Oct. 31, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in Wonderland: Miami hosted by Microdose to be held at the Mana Wynwood Convention Center in Miami, FL on November 3-5, 2022.
Oct 28, 2022 07:00 am ET
Numinus Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness
Clinical program broadens access to ketamine-assisted therapy for an underserved population
Oct 28, 2022 07:00 am ET
Numinus Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness
Clinical program broadens access to ketamine-assisted therapy for an underserved population
Oct 07, 2022 07:00 am ET
Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, October 13, 2022
VANCOUVER, BC, Oct. 7, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will participate in a Water Tower Research Fireside Chat on Thursday, October 13, 2022, at 2:30 p.m. ET / 11:30 a.m. PT.
Oct 07, 2022 07:00 am ET
Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, October 13, 2022
VANCOUVER, BC, Oct. 7, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will participate in a Water Tower Research Fireside Chat on Thursday, October 13, 2022, at 2:30 p.m. ET / 11:30 a.m. PT.
Oct 05, 2022 07:30 am ET
Numinus Develops Mushroom Tea for Use in Psychedelic Research
Psilocybin-containing tea bag offers substitute for whole mushrooms and other solid therapeutics
Oct 05, 2022 07:30 am ET
Numinus Develops Mushroom Tea for Use in Psychedelic Research
Psilocybin-containing tea bag offers substitute for whole mushrooms and other solid therapeutics
Sep 29, 2022 04:01 pm ET
Numinus to Participate in the Cantor Neurology & Psychiatry Conference on October 6-7, 2022
VANCOUVER, BC, Sept. 29, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the Cantor Neurology & Psychiatry Conference to be held at The Ritz-Carlton in San Francisco on October 6-7, 2022.
Sep 29, 2022 04:01 pm ET
Numinus to Participate in the Cantor Neurology & Psychiatry Conference on October 6-7, 2022
VANCOUVER, BC, Sept. 29, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the Cantor Neurology & Psychiatry Conference to be held at The Ritz-Carlton in San Francisco on October 6-7, 2022.
Sep 22, 2022 07:00 am ET
Numinus Expands Ketamine Therapy for Mental Health in Montreal and announces new brand awareness initiatives
New Montreal space will focus on treating depression, addiction and other common disordersNuminus announces sponsorship of East Forest North American tourCompany also announces new PR and Marketing partnersVANCOUVER, BC, Sept. 22, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced the opening of a new clinic in Montreal that will replace an existing downtown clinic. The new site, in the Plateau neighbourhood, will have
Sep 22, 2022 07:00 am ET
Numinus Expands Ketamine Therapy for Mental Health in Montreal and announces new brand awareness initiatives
New Montreal space will focus on treating depression, addiction and other common disordersNuminus announces sponsorship of East Forest North American tourCompany also announces new PR and Marketing partnersVANCOUVER, BC, Sept. 22, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced the opening of a new clinic in Montreal that will replace an existing downtown clinic. The new site, in the Plateau neighbourhood, wil
Sep 19, 2022 07:00 am ET
Numinus Now Offers Ketamine-Assisted Therapy in Toronto
Treatment will be offered at the Neurology Centre of Toronto in Forest Hill
Sep 19, 2022 07:00 am ET
Numinus Now Offers Ketamine-Assisted Therapy in Toronto
Treatment will be offered at the Neurology Centre of Toronto in Forest Hill
Sep 13, 2022 07:00 am ET
Numinus provides update on acquisition integration and announces new client financing options
US clinics acquired from Novamind demonstrating continued growthPhysical rebranding of clinics is underwayAnnouncing new client financing options in CanadaVANCOUVER, BC, Sept. 13, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) is pleased to provide an update on the integration of the Novamind acquisition, which completed on June 10, 2022.
Sep 13, 2022 07:00 am ET
Numinus provides update on acquisition integration and announces new client financing options
US clinics acquired from Novamind demonstrating continued growthPhysical rebranding of clinics is underwayAnnouncing new client financing options in CanadaVANCOUVER, BC, Sept. 13, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) is pleased to provide an update on the integration of the Novamind acquisition, which completed on June 10, 2022.
Aug 31, 2022 07:30 am ET
Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
VANCOUVER, BC, Aug. 31, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the H.C. Wainwright 24th Annual Global Investment Conference to be held at the Lotte New York Palace Hotel in New York City on September 12-14, 2022.
Aug 31, 2022 07:30 am ET
Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
VANCOUVER, BC, Aug. 31, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the H.C. Wainwright 24th Annual Global Investment Conference to be held at the Lotte New York Palace Hotel in New York City on September 12-14, 2022.
Jul 14, 2022 04:01 pm ET
Numinus Wellness Inc. Reports Q3 2022 Results
Revenues grew 32% year-over-year to $0.74 million for the quarterClinic network revenues grew 59.5% from the same quarter last year and 7.5% compared to prior quarter Achieved 24.4% gross margin and $180,845 gross profit of during Q3 2022 Ended quarter with strong cash position of $41.8 millionCompleted acquisition of Novamind, positioning Numinus as a leading, integrated mental healthcare company providing psychedelic-assisted therapiesAll financial results are reported in Canadian dollars unless otherwise stated.
Jul 14, 2022 04:01 pm ET
Numinus Wellness Inc. Reports Q3 2022 Results
Revenues grew 32% year-over-year to $0.74 million for the quarterClinic network revenues grew 59.5% from the same quarter last year and 7.5% compared to prior quarter Achieved 24.4% gross margin and $180,845 gross profit of during Q3 2022 Ended quarter with strong cash position of $41.8 millionCompleted acquisition of Novamind, positioning Numinus as a leading, integrated mental healthcare company providing psychedelic-assisted therapiesAll financial results are reported in Canadian dollars unless otherwise stated.
Jul 06, 2022 07:30 am ET
Numinus to Host Q3 2022 Results Conference Call on July 14, 2022
VANCOUVER, BC, July 6, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended May 31, 2022, after market close on Thursday, July 14, 2022.
Jun 27, 2022 07:00 am ET
Numinus Unveils New Logo and Brand Identity
New branding unifies Numinus' presence across North America
Jun 27, 2022 07:00 am ET
Numinus Unveils New Logo and Brand Identity
New branding unifies Numinus' presence across North America
Jun 23, 2022 07:00 am ET
Numinus Pilots Mental Health Program for Corporate Clients in Utah
VANCOUVER, BC, June 23, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce the launch of a Utah-based pilot program to help businesses improve employee mental health by offering ketamine-assisted psychotherapy (KAP) as a health benefit for eligible employees ("Corporate KAP").
Jun 23, 2022 07:00 am ET
Numinus Pilots Mental Health Program for Corporate Clients in Utah
VANCOUVER, BC, June 23, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce the launch of a Utah-based pilot program to help businesses improve employee mental health by offering ketamine-assisted psychotherapy (KAP) as a health benefit for eligible employees ("Corporate KAP").
Jun 22, 2022 07:00 am ET
Numinus Applies for International Patent Filing of Psychedelics Production Process
Filing would offer added protection to IP already submitted to USPTO
Jun 22, 2022 07:00 am ET
Numinus Applies for International Patent Filing of Psychedelics Production Process
Filing would offer added protection to IP already submitted to USPTO
Jun 21, 2022 04:05 pm ET
Numinus to Participate in the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022
VANCOUVER, BC, June 21, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the H.C. Wainwright 1st Annual Mental Health Conference to be held at the Lotte New York Palace Hotel in New York City on Monday, June 27, 2022.
Jun 21, 2022 04:05 pm ET
Numinus to Participate in the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022
VANCOUVER, BC, June 21, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the H.C. Wainwright 1st Annual Mental Health Conference to be held at the Lotte New York Palace Hotel in New York City on Monday, June 27, 2022.
Jun 13, 2022 02:05 pm ET
The Power Play by The Market Herald Releases Interviews with Datametrex, Numinus Wellness, Eat Well Group, and Baroyeca Gold & Silver
VANCOUVER, BC / ACCESSWIRE/ June 13, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Datametrex, Numinus Wellness, Eat Well Group, and Baroyeca Gold & Silver on their latest news.
Jun 10, 2022 07:30 pm ET
Novamind Obtains Final Order for Plan of Arrangement from the Supreme Court of British Columbia and Completes Acquisition by Numinus Wellness Inc.
TORONTO, ON / ACCESSWIRE / June 10, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announced today that the Company has completed its previously announced acquisition by Numinus Wellness Inc. (TSX:NUMI)(OTCQX:NUMIF) ("Numinus") by way of a plan of arrangement (the "Transaction") following receipt of a final order from the Supreme Court of British Columbia.
Jun 10, 2022 07:30 pm ET
Numinus completes acquisition of Novamind and announces executive appointments
Transaction has completed following shareholder and court approvalsNovamind shareholders and RSU holders have been issued 0.84 Numinus shares per Novamind shareAs a result of the acquisition, Novamind has ceased trading on the Canadian Securities Exchange (CSE)Reid Robison has been appointed Chief Clinical Officer and Paul Thielking has been appointed Chief Science OfficerMichael Tan has been promoted to President and Chief Operating OfficerVANCOUVER, BC, June 10, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) is pleased to announce the acquisition (
Jun 10, 2022 07:30 pm ET
Numinus completes acquisition of Novamind and announces executive appointments
Transaction has completed following shareholder and court approvalsNovamind shareholders and RSU holders have been issued 0.84 Numinus shares per Novamind shareAs a result of the acquisition, Novamind has ceased trading on the Canadian Securities Exchange (CSE)Reid Robison has been appointed Chief Clinical Officer and Paul Thielking has been appointed Chief Science OfficerMichael Tan has been promoted to President and Chief Operating OfficerVANCOUVER, BC, June 10, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) is pleased to announce the acquis
Jun 08, 2022 04:05 pm ET
Numinus announces shareholder approval of resolution in connection with the proposed acquisition of Novamind
Novamind shareholders, at a separate meeting held today, have also approved the transactionTransaction expected to be completed on or about June 10, 2022VANCOUVER, BC, June 8, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) is pleased to announce shareholders have approved the Company's resolution to issue common shares in the capital of Numinus (the "Common Shares") in connection with the proposed acquisition (the "Transaction) of Novamind Inc. ("Novamind"). Novamind shareholders have also voted to approve the acquisition of Novamind by Numinus, pur
Jun 08, 2022 04:05 pm ET
Numinus announces shareholder approval of resolution in connection with the proposed acquisition of Novamind
Novamind shareholders, at a separate meeting held today, have also approved the transactionTransaction expected to be completed on or about June 10, 2022VANCOUVER, BC, June 8, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) is pleased to announce shareholders have approved the Company's resolution to issue common shares in the capital of Numinus (the "Common Shares") in connection with the proposed acquisition (the "Transaction) of Novamind Inc. ("Novamind"). Novamind shareholders have also voted to approve the acquisition of Novamind by Numin
May 31, 2022 07:00 am ET
Numinus announces ISS recommends shareholders vote in favor of the share issuance to acquire Novamind
ISS states that the proposed acquisition is in the best interest of Numinus shareholdersShareholders are encouraged to vote their common shares prior to the proxy deadline of June 6, 2022 at 11:00 a.m. PT. For any questions on voting, please contact Laurel Hill Advisory Group at 1-877-452-7184 (North American Toll Free) or by email at [email protected], BC, May 31, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) is pleased to announce that Institutional Shareholder Services ("ISS"), a leading proxy advisory firm that provides independ
May 31, 2022 07:00 am ET
Numinus announces ISS recommends shareholders vote in favor of the share issuance to acquire Novamind
ISS states that the proposed acquisition is in the best interest of Numinus shareholdersShareholders are encouraged to vote their common shares prior to the proxy deadline of June 6, 2022 at 11:00 a.m. PT. For any questions on voting, please contact Laurel Hill Advisory Group at 1-877-452-7184 (North American Toll Free) or by email at [email protected], BC, May 31, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) is pleased to announce that Institutional Shareholder Services ("ISS"), a leading proxy advisory firm that provides i
May 16, 2022 07:30 am ET
Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment
Approval Marks Numinus' First use of Psilocybin-Assisted Therapy Treatment Outside of Clinical Trials
May 16, 2022 07:30 am ET
Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment
Approval Marks Numinus' First use of Psilocybin-Assisted Therapy Treatment Outside of Clinical Trials
May 11, 2022 07:30 am ET
Numinus to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022
VANCOUVER, BC, May 11, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will participate in a fireside chat hosted by Patrick Trucchio, H.C. Wainwright Research Analyst, at the H.C. Wainwright Global Investment Conference to be held at the Fontainebleau Miami Beach Hotel in Miami, FL on Wednesday, May 25th at 3:30 p.m. ET.
May 11, 2022 07:30 am ET
Numinus to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022
VANCOUVER, BC, May 11, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will participate in a fireside chat hosted by Patrick Trucchio, H.C. Wainwright Research Analyst, at the H.C. Wainwright Global Investment Conference to be held at the Fontainebleau Miami Beach Hotel in Miami, FL on Wednesday, May 25th at 3:30 p.m. ET.
May 10, 2022 07:30 am ET
Numinus Mails Materials for Special Meeting of Shareholders and Announces Interim Court Order for Plan of Arrangement
Shareholders are encouraged to vote their common shares prior to the proxy deadline of June 6, 2022 at 11:00 a.m. PT
May 10, 2022 07:30 am ET
Numinus Mails Materials for Special Meeting of Shareholders and Announces Interim Court Order for Plan of Arrangement
Shareholders are encouraged to vote their common shares prior to the proxy deadline of June 6, 2022 at 11:00 a.m. PT
May 09, 2022 07:30 am ET
Numinus to Participate in Upcoming Research & Industry Conferences
Numinus leaders will speak at Catalyst, Psychedelic Therapeutics & From Research to Reality
May 09, 2022 07:30 am ET
Numinus to Participate in Upcoming Research & Industry Conferences
Numinus leaders will speak at Catalyst, Psychedelic Therapeutics & From Research to Reality
Apr 29, 2022 08:35 am ET
KCSA Psychedelics Virtual Investor Conference Presentations Now Available for On-Demand Viewing
Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the April 27th and 28th KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing. REGISTER...
Apr 29, 2022 08:30 am ET
Numinus Announces the Music as Medicine Event Series
Music As Medicine by Numinus is a series of Meditative Musical Experiences & Creative Content Featuring Jon Hopkins, East Forest And Superposition
Apr 29, 2022 08:30 am ET
Numinus Announces the Music as Medicine Event Series
Music As Medicine by Numinus is a series of Meditative Musical Experiences & Creative Content Featuring Jon Hopkins, East Forest And Superposition
Apr 25, 2022 08:35 am ET
KCSA Psychedelics Virtual Investor Conference Agenda Announced for April 27th & 28th
Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference to be held on...
Apr 14, 2022 04:00 pm ET
Numinus Wellness Inc. Reports Q2 2022 Results
Revenues grew 240% year-over-year to $0.8 million for the quarterAchieved 29.1% gross margin during Q2 2022, compared to 6.5% in Q1 2022, due to a larger proportion of higher-margin services being provided across wellness clinicsGenerated gross profit of $228,759 during Q2 2022, a 349% increase from prior quarter Recently announced proposed acquisition of Novamind expected to grow annual revenues more than five times from current levels; positions Numinus as a leading, integrated mental healthcare company providing psychedelic-assisted therapiesEnded quarter with strong cash position of $48.
Apr 14, 2022 04:00 pm ET
Numinus Wellness Inc. Reports Q2 2022 Results
Revenues grew 240% year-over-year to $0.8 million for the quarterAchieved 29.1% gross margin during Q2 2022, compared to 6.5% in Q1 2022, due to a larger proportion of higher-margin services being provided across wellness clinicsGenerated gross profit of $228,759 during Q2 2022, a 349% increase from prior quarter Recently announced proposed acquisition of Novamind expected to grow annual revenues more than five times from current levels; positions Numinus as a leading, integrated mental healthcare company providing psychedelic-assisted therapiesEnded quarter with strong cash position of $48.
Apr 12, 2022 08:18 am ET
IIROC Trade Resumption - NUMI
TORONTO, April 12, 2022 /CNW/ - Trading resumes in:
Apr 12, 2022 07:00 am ET
Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research
Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory Shared mission of responsibly reintroducing psychedelic therapy to mental healthcare Hosting clinical trials for MDMA (MAPS Public Benefit Corporation), psilocybin (the Usona Institute), LSD (MindMed) and ketamine (the University of Utah)Combined C$10 million in annual pro-forma revenue based on the trailing four quartersAcquisition is expected to generate C$3 million in annual cost synergiesTransaction expected to
Apr 12, 2022 07:00 am ET
Numinus to Acquire Novamind, Creating the North American Industry Leader in Psychedelic Therapy and Research
Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory Shared mission of responsibly reintroducing psychedelic therapy to mental healthcare Hosting clinical trials for MDMA (MAPS Public Benefit Corporation), psilocybin (the Usona Institute), LSD (MindMed) and ketamine (the University of Utah)Combined C$10 million in annual pro-forma revenue based on the trailing four quartersAcquisition is expected to generate C$3 million in annual cost synergiesTransaction expected to
Apr 11, 2022 08:17 am ET
IIROC Trading Halt - NUMI
TORONTO, April 11, 2022 /CNW/ - The following issues have been halted by IIROC:
Apr 07, 2022 07:30 am ET
Numinus to Participate in Upcoming Investor Conferences in April 2022
VANCOUVER, BC, April 7, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will participate in two upcoming investor conferences:
Apr 07, 2022 07:30 am ET
Numinus to Participate in Upcoming Investor Conferences in April 2022
VANCOUVER, BC, April 7, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will participate in two upcoming investor conferences:
Apr 01, 2022 07:30 am ET
Numinus to Host Q2 2022 Results Conference Call on April 14, 2022
VANCOUVER, BC, April 1, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended February 28, 2022, after market close on Thursday, April 14, 2022.
Apr 01, 2022 07:30 am ET
Numinus to Host Q2 2022 Results Conference Call on April 14, 2022
VANCOUVER, BC, April 1, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended February 28, 2022, after market close on Thursday, April 14, 2022.
Mar 30, 2022 07:30 am ET
Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS
Update marks the first MDMA-assisted therapy session at a Numinus clinic
Mar 30, 2022 07:30 am ET
Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS
Update marks the first MDMA-assisted therapy session at a Numinus clinic
Mar 15, 2022 07:30 am ET
Numinus to Participate in Maxim's 2022 Virtual Growth Conference on March 28-30, 2022
VANCOUVER, BC, March 15, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in Maxim Group's 2022 Virtual Growth Conference to be held virtually on March 28-30, 2022.
Mar 15, 2022 07:30 am ET
Numinus to Participate in Maxim's 2022 Virtual Growth Conference on March 28-30, 2022
VANCOUVER, BC, March 15, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in Maxim Group's 2022 Virtual Growth Conference to be held virtually on March 28-30, 2022.
Mar 14, 2022 07:30 am ET
Numinus Expands Natural Psychedelic Research with New Biosecurity License
Federal Containment Level 2 license will support testing and validation for studies and sale of natural products
Mar 14, 2022 07:30 am ET
Numinus Expands Natural Psychedelic Research with New Biosecurity License
Federal Containment Level 2 license will support testing and validation for studies and sale of natural products
Mar 09, 2022 06:30 am ET
Numinus Adds Ayahuasca & San Pedro to Federal License for Psychedelic Research
Health Canada license renewal expands Numinus' extensive list of permissible R&D activities
Mar 09, 2022 06:30 am ET
Numinus Adds Ayahuasca & San Pedro to Federal License for Psychedelic Research
Health Canada license renewal expands Numinus' extensive list of permissible R&D activities
Feb 28, 2022 04:39 pm ET
Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders
VANCOUVER, BC, Feb. 28, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting"), held earlier today. A total of 26,215,003 common shares, or 12.73% of the issued and outstanding common shares of the Company as at the record date of January 24, 2022, were represented either in person or by proxy at the Meeting.
Feb 28, 2022 04:39 pm ET
Numinus Wellness Announces Voting Results From its Annual General and Special Meeting of Shareholders
VANCOUVER, BC, Feb. 28, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting"), held earlier today. A total of 26,215,003 common shares, or 12.73% of the issued and outstanding common shares of the Company as at the record date of January 24, 2022, were represented either in person or by proxy at the Meeting.
Feb 10, 2022 06:30 am ET
Numinus to Participate in AAAS 2022 Annual Meeting on February 17-20, 2022
Dr. Devon Christie, Dr. Robin Carhart-Harris, Dr. Frederick Barrett and Tura Patterson will discuss "Psychedelic Research: Moving Beyond the Social and Political Stigma"
Feb 01, 2022 06:30 am ET
Numinus Appoints New Bioscience Advisors to Advance IP Development
Advisors lead their fields in patent law, nutraceuticals & ethnobotany
Jan 27, 2022 07:30 am ET
Numinus Identified as a Licensed Psilocybin Supplier by Health Canada
Health Canada list identifies select companies that can supply psilocybin to approved applicants through the Special Access Program for patient treatment
Jan 27, 2022 07:30 am ET
Numinus Identified as a Licensed Psilocybin Supplier by Health Canada
Health Canada list identifies select companies that can supply psilocybin to approved applicants through the Special Access Program for patient treatment
Jan 26, 2022 04:15 pm ET
Numinus Wellness Inc. Graduates to the OTCQX Best Market
VANCOUVER, BC, Jan. 26, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it will commence trading on the OTCQX® Best Market in the United States when the market opens tomorrow, Thursday, January 27, 2022. Numinus' shares previously traded on the Pink market and will continue to trade under the symbol "NUMIF."
Jan 26, 2022 04:15 pm ET
Numinus Wellness Inc. Graduates to the OTCQX Best Market
VANCOUVER, BC, Jan. 26, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it will commence trading on the OTCQX® Best Market in the United States when the market opens tomorrow, Thursday, January 27, 2022. Numinus' shares previously traded on the Pink market and will continue to trade under the symbol "NUMIF."
Jan 25, 2022 07:00 am ET
Numinus to Participate in Citi's Psychedelic Drug Call Series on February 2, 2022
VANCOUVER, BC, Jan. 25, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in Citi's Psychedelic Drug Call Series to be hosted virtually on Wednesday, February 2, 2022.
Jan 20, 2022 03:01 pm ET
Numinus Wellness Inc. Reports Q1 2022 Results
Ended quarter with strong cash position of $53.9 million Revenues grew 245% year-over-year to $0.8 million for the quarter Generated gross profit of $50,965 during the quarter, representing a 6.5% gross margin Well-positioned to offer psychedelic-assisted psychotherapy services through Canada's newly expanded Special Access Program Clinical trial application made to Health Canada to begin Phase 1 study for proprietary psilocybe extract MAPS-sponsored MDMA-Assisted Therapy for PTSD study to begin shortly; approvals received from Health Canada and the Institutional Review BoardAll financial re
Jan 20, 2022 03:01 pm ET
Numinus Wellness Inc. Reports Q1 2022 Results
Ended quarter with strong cash position of $53.9 million Revenues grew 245% year-over-year to $0.8 million for the quarter Generated gross profit of $50,965 during the quarter, representing a 6.5% gross margin Well-positioned to offer psychedelic-assisted psychotherapy services through Canada's newly expanded Special Access Program Clinical trial application made to Health Canada to begin Phase 1 study for proprietary psilocybe extract MAPS-sponsored MDMA-Assisted Therapy for PTSD study to begin shortly; approvals received from Health Canada and the Institutional Review BoardAll financial re
Jan 19, 2022 07:00 am ET
Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial
Numinus has received approvals from Health Canada and the Institutional Ethics Review Board
Jan 19, 2022 07:00 am ET
Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial
Numinus has received approvals from Health Canada and the Institutional Ethics Review Board
Jan 14, 2022 07:00 am ET
Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product
The trial evaluates Numinus' first trademarked product and patent-pending production process
Jan 14, 2022 07:00 am ET
Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product
The trial evaluates Numinus' first trademarked product and patent-pending production process
Jan 13, 2022 06:32 pm ET
Numinus Announces Cancellation and Rescheduling of Annual General Meeting of Shareholders
VANCOUVER, BC, Jan. 13, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today that its annual general meeting of shareholders (the "AGM"), which was originally scheduled to be held on Friday, January 21, 2022, has been cancelled and rescheduled to be held on February 28, 2022. The Company's Board of Directors determined that it would be in the best interests of the Company to reschedule the AGM for a variety of reasons, including
Jan 13, 2022 06:32 pm ET
Numinus Announces Cancellation and Rescheduling of Annual General Meeting of Shareholders
VANCOUVER, BC, Jan. 13, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today that its annual general meeting of shareholders (the "AGM"), which was originally scheduled to be held on Friday, January 21, 2022, has been cancelled and rescheduled to be held on February 28, 2022. The Company's Board of Directors determined that it would be in the best interests of the Company to reschedule the AGM for a variety of reasons, including a chang
Jan 11, 2022 08:00 am ET
TMX Group Equity Financing Statistics - December 2021
Toronto Stock Exchange, TSX Venture Exchange
Jan 07, 2022 04:04 pm ET
Numinus Announces Q1 2022 Results Conference Call Update
VANCOUVER, BC, Jan. 7, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announces that it is rescheduling its Q1 2022 results conference call and reporting of its Q1 2022 financial results to January 20, 2022 (previously January 13, 2022). This change is a result of staffing challenges related to COVID-19.
Jan 07, 2022 04:04 pm ET
Numinus Announces Q1 2022 Results Conference Call Update
VANCOUVER, BC, Jan. 7, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announces that it is rescheduling its Q1 2022 results conference call and reporting of its Q1 2022 financial results to January 20, 2022 (previously January 13, 2022). This change is a result of staffing challenges related to COVID-19.
Jan 05, 2022 07:00 am ET
Numinus to Host Q1 2022 Results Conference Call on January 13, 2022
VANCOUVER, BC, Jan. 5, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended November 30, 2021, after market close on Thursday, January 13, 2022.
Jan 05, 2022 07:00 am ET
Numinus to Host Q1 2022 Results Conference Call on January 13, 2022
VANCOUVER, BC, Jan. 5, 2022 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter ended November 30, 2021, after market close on Thursday, January 13, 2022.
Dec 22, 2021 04:00 pm ET
Numinus Wellness Commends Health Canada on Special Access Programme Amendments to Restore Potential Access to Psychedelic Medicines
Policy amendment allows practitioners to request access to psychedelic drugs for patients with serious or life-threatening conditions on a case-by-case basis
Dec 22, 2021 04:00 pm ET
Numinus Wellness Commends Health Canada on Special Access Programme Amendments to Restore Potential Access to Psychedelic Medicines
Policy amendment allows practitioners to request access to psychedelic drugs for patients with serious or life-threatening conditions on a case-by-case basis
Dec 16, 2021 10:30 am ET
Numinus Wellness Opens the Market
TORONTO, Dec. 16, 2021 /CNW/ - Payton Nyquvest, Founder and Chief Executive Officer, Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) and his team joined Michael Kousaie, Vice-President, Strategy and Product Innovation, TMX Group, to celebrate the Company's new listing on Toronto Stock Exchange and open the market.
Dec 14, 2021 05:00 pm ET
Numinus Wellness Inc. to Commence Trading on the TSX on December 16, 2021
Numinus will ring the TSX opening bell to celebrate this milestone
Dec 14, 2021 05:00 pm ET
Numinus Wellness Inc. to Commence Trading on the TSX on December 16, 2021
Numinus will ring the TSX opening bell to celebrate this milestone
Dec 09, 2021 04:02 pm ET
Numinus Wellness Inc. Reports Q4 and Year End 2021 Results
Ended the year with strong cash position of $59.2 million Revenues grew 81% year-over-year to $0.5 million for Q4 2021 Revenues grew 72% year-over-year to $1.5 million for FY 2021 Gross profit of $31,818 for Q4 2021 Completed the acquisition of the Neurology Centre of Toronto in September 2021 Two clinical trials about to launch: Phase 1 study for proprietary psilocybe extract and Phase 3 open label extension study partnership with MAPS for MDMA for PTSD Recently received conditional approval to graduate to the TSX (from the TSX Venture) All financial results are reported in Canadian dollars
Dec 09, 2021 04:02 pm ET
Numinus Wellness Inc. Reports Q4 and Year End 2021 Results
Ended the year with strong cash position of $59.2 million Revenues grew 81% year-over-year to $0.5 million for Q4 2021 Revenues grew 72% year-over-year to $1.5 million for FY 2021 Gross profit of $31,818 for Q4 2021 Completed the acquisition of the Neurology Centre of Toronto in September 2021 Two clinical trials about to launch: Phase 1 study for proprietary psilocybe extract and Phase 3 open label extension study partnership with MAPS for MDMA for PTSD Recently received conditional approval to graduate to the TSX (from the TSX Venture) All financial results are reported in Canadian dollars
Nov 30, 2021 07:30 am ET
Numinus to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th
VANCOUVER, BC, Nov. 30, 2021 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the H.C. Wainwright 2nd Annual Psychedelics Conference to be hosted virtually on Monday, December 6, 2021.
Nov 30, 2021 07:30 am ET
Numinus to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th
VANCOUVER, BC, Nov. 30, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the H.C. Wainwright 2nd Annual Psychedelics Conference to be hosted virtually on Monday, December 6, 2021.
Nov 29, 2021 04:30 am ET
Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans
Analytical testing will accelerate Numinus' Research and Development capabilities and generate revenue through third-party clients
Nov 29, 2021 04:30 am ET
Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans
Analytical testing will accelerate Numinus' Research and Development capabilities and generate revenue through third-party clients
Nov 26, 2021 07:30 am ET
Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange
VANCOUVER, BC, Nov. 26, 2021 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange ("TSX") to graduate its listing from the TSX Venture Exchange (the "TSXV") to the TSX.
Nov 26, 2021 07:30 am ET
Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange
VANCOUVER, BC, Nov. 26, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange ("TSX") to graduate its listing from the TSX Venture Exchange (the "TSXV") to the TSX.
Nov 25, 2021 05:00 pm ET
Numinus Announces Departure of Stacey Wallin
VANCOUVER, BC, Nov. 25, 2021 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today following the conclusion of several weeks of discussions that Stacey Wallin, former Chief Strategy Officer, is no longer with the Company.
Nov 25, 2021 05:00 pm ET
Numinus Announces Departure of Stacey Wallin
VANCOUVER, BC, Nov. 25, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announced today following the conclusion of several weeks of discussions that Stacey Wallin, former Chief Strategy Officer, is no longer with the Company.
Nov 22, 2021 07:30 am ET
Numinus to Host Q4 and 2021 Annual Results Conference Call on December 9, 2021
VANCOUVER, BC, Nov. 22, 2021 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter and year ended August 31, 2021 after market close on Thursday, December 9, 2021.
Nov 22, 2021 07:30 am ET
Numinus to Host Q4 and 2021 Annual Results Conference Call on December 9, 2021
VANCOUVER, BC, Nov. 22, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, will release its financial results for the quarter and year ended August 31, 2021 after market close on Thursday, December 9, 2021.
Nov 19, 2021 07:30 am ET
Numinus to Begin Trading on the OTC Under Symbol NUMIF
VANCOUVER, BC, Nov. 19, 2021 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its ticker symbol on the OTC Pink market in the United States will change to "NUMIF" (previously "LKYSF") when the market opens on Monday, November 22, 2021.
Nov 19, 2021 07:30 am ET
Numinus to Begin Trading on the OTC Under Symbol NUMIF
VANCOUVER, BC, Nov. 19, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its ticker symbol on the OTC Pink market in the United States will change to "NUMIF" (previously "LKYSF") when the market opens on Monday, November 22, 2021.
Nov 10, 2021 04:00 am ET
Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials
Numinus will manage two new clinics in Montreal and Vancouver to host trials.
Nov 10, 2021 04:00 am ET
Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials
Numinus will manage two new clinics in Montreal and Vancouver to host trials.
Oct 26, 2021 09:00 am ET
Numinus to Participate in Microdose Hosted Events: Psychedelic Capital and Wonderland: Miami
VANCOUVER, BC, Oct. 26, 2021 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in two upcoming events hosted by Microdose:
Oct 26, 2021 09:00 am ET
Numinus to Participate in Microdose Hosted Events: Psychedelic Capital and Wonderland: Miami
VANCOUVER, BC, Oct. 26, 2021 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in two upcoming events hosted by Microdose:
Oct 20, 2021 09:00 am ET
Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product
Finalized study design and protocol mark major milestone to investigate natural Psilocybin
Oct 20, 2021 09:00 am ET
Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product
Finalized study design and protocol mark major milestone to investigate natural Psilocybin
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2023 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.